ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 963

Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept

Sarah Goglin1, David Wofsy2, Miriam G. Cisternas3 and Maria Dall'era1, 1Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3MGC Data Services, Carlsbad, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome in lupus nephritis. To do this, we utilized data from the Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study (ACCESS) to identify predictors of renal response at 6 months in patients with lupus nephritis.

Methods: 134 subjects with class III or IV lupus nephritis were randomized to low-dose intravenous cyclophosphamide (IVC) or low-dose IVC with abatacept. Renal response was assessed at 24 weeks. Complete renal response (CR) was defined as: urine protein-to-creatinine ratio (UPCR) <0.5; serum creatinine (Cr) normal, or if abnormal, within 25% of baseline; and adherence to steroid taper regimen. Partial renal response (PR) was defined as: >50% improvement in UPCR; with the same parameters for serum Cr and steroid taper as CR. For the purposes of this analysis, we defined renal response as a composite of CR and PR. We identified possible predictors of renal response, including baseline demographic, clinical, laboratory, and histologic characteristics, as well as clinical and laboratory data obtained within the first 3 months of therapy. We calculated univariate odds ratios (ORs) and 95% confidence intervals (CIs) for renal response for each putative predictor, in the sample as a whole and within each treatment arm. We then conducted a multivariable logistic regression analysis, including all significant predictors (defined as p<0.05) from the univariate regressions.

Results: Reduction in proteinuria by at least 25% by week 12 was the strongest predictor of CR or PR at week 24 (OR 8.1; p<0.05). Normalization of C4 and normalization of C3 and C4 by week 12 were also predictive of renal response at week 24 (ORs 4.5 and 4.6 respectively; p<0.05). Reduction in proteinuria by at least 25% and normalization of C4 remained significant independent predictors in the multivariate analysis (ORs 13.3 and 3.6 respectively; p<0.05). This was independent of the treatment arm. None of the baseline characteristics was predictive of renal response.

Conclusion: This study demonstrates that a reduction of at least 25% in proteinuria at 3 months and normalization of C4 levels at 3 months independently predict renal response to therapy with low-dose IVC, with or without abatacept, at 6 months in patients with lupus nephritis. This supports previous findings from the Aspreva Lupus Management Study (ALMS), although reduction in proteinuria was a stronger predictor in this analysis. In contrast to the ALMS analysis, we did not find that time since lupus nephritis diagnosis or baseline eGFR were predictors of renal response. Future studies should address these and other, novel biomarkers so that we can more accurately predict which patients will respond well to treatment.


Disclosure:

S. Goglin,
None;

D. Wofsy,
None;

M. G. Cisternas,
None;

M. Dall’era,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-in-proteinuria-and-normalization-of-c4-complement-levels-predict-response-to-treatment-of-lupus-nephritis-with-low-dose-pulse-cyclophosphamide-and-abatacept/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology